ArticleAsian Pacific journal of cancer prevention : APJCP2025
Association of P53 Codon 72 Polymorphism with Ovarian Cancer: An Institutional Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymorphism of P53 gene has been explored worldwide to know the genetic predisposition of ovarian cancer, however.literature reports inconsistent association between codon 72 polymorphism and ovarian cancer risk.Several studies have reported a higher incidence of ovarian cancer associated with the Pro variant, while others found non-significant association. Present study has been conducted to investigate the association of codon 72 polymorphism of p53 gene with ovarian cancer risk in Asian population and to correlate them with clinicopathological characteristics of patients. METHODOLOGY: The study was conducted on 60 ovarian cancer patients and 60 healthy women..Single-nucleotide polymorphism (SNP) G>C (Arg>Pro) transition at codon 72 of exon 4 (rs1042522) in the P53 gene Has been analysed.DNA was extracted by using the DNA Sure Blood Mini Kit (GeNei TM).The genetic polymorphism in P53 genes was assessed by Allele-specific polymerase chain reaction(ASO-PCR).X2,Fisher exact test and odds ratio[0R] at 95% confidence interval [CI]) were used for statistical analysis.
resultsThe distribution of Arg/Arg, Arg/Pro and Pro/Pro genotype of codon 72 of theP53 gene was 30%,50%, and 20% in the ovarian cancer patients and 60%,31.6%, and 8.3%, respectively in healthy individuals. Increased frequency of Pro/Pro allele. was associated with the risk of ovarian cancer as revealed by statistically significant values at p-0.003.(OR=4.8;95%CI 1.46-15.72). Patients who expressed P53 proline allele might be at higher risk of developing ovarian cancer as compared with those who expressed P53 Arg allele (p= 0.003).However small sample size is the limitation of present study.Analysis of bigger group of ovarian cancer patients may robust the genetic predisposition of P53 codon 72 in ovarian carcinogenesis.
conclusionGenetic predisposition of proline allele of P53 gene in ovarian carcinoma might be explored as early diagnostic marker of ovarian cancer and to go ahead towards gene-targeted drug therapy for better clinical outcome as well as to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.